Acute Kidney Injury in COVID-19 Patients Receiving Remdesivir: A Systematic Review and Meta-analysis of Randomized Clinical Trials

Overview

Journal Clinics (Sao Paulo)

Publisher Elsevier

Specialty General Medicine

Date 2023 Apr 30

PMID 37120984

Authors

Golnaz Shams

Asma Kazemi

Khatereh Jafaryan

Mohammad Hossein Morowvat

Payam Peymani

Iman Karimzadeh

Affiliations

Soon will be listed here.

Abstract

Objectives: Remdesivir is an antiviral agent with positive effects on the prognosis of Coronavirus Disease (COVID-19). However, there are concerns about the detrimental effects of remdesivir on kidney function which might consequently lead to Acute Kidney Injury (AKI). In this study, we aim to determine whether remdesivir use in COVID-19 patients increases the risk of AKI.

Methods: PubMed, Scopus, Web of Science, the Cochrane Central Register of Controlled Trials, medRxiv, and bioRxiv were systematically searched until July 2022, to find Randomized Clinical Trials (RCT) that evaluated remdesivir for its effect on COVID-19 and provided information on AKI events. A random-effects model meta-analysis was conducted and the certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation. The primary outcomes were AKI as a Serious Adverse Event (SAE) and combined serious and non-serious Adverse Events (AE) due to AKI.

Results: This study included 5 RCTs involving 3095 patients. Remdesivir treatment was not associated with a significant change in the risk of AKI classified as SAE (Risk Ratio [RR]: 0.71, 95% Confidence Interval [95% CI] 0.43‒1.18, p = 0.19, low-certainty evidence) and AKI classified as any grade AEs (RR = 0.83, 95% CI 0.52‒1.33, p = 0.44, low-certainty evidence), compared to the control group.

Conclusion: Our study suggested that remdesivir treatment probably has little or no effect on the risk of AKI in COVID-19 patients.

Citing Articles

Association of Antiviral Drugs for the Treatment of COVID-19 With Acute Renal Failure.

Kamo M, Sogawa R, Shimanoe C In Vivo. 2024; 38(4):1841-1846.

PMID: 38936945 PMC: 11215623. DOI: 10.21873/invivo.13637.

Adverse effects of remdesivir for the treatment of acute COVID-19 in the pediatric population: a retrospective observational study.

Schulz A, Huynh N, Heger M, Bakir M Mol Cell Pediatr. 2024; 11(1):2.

PMID: 38381231 PMC: 10881938. DOI: 10.1186/s40348-024-00175-9.

Evolving Clinical Manifestations and Outcomes in COVID-19 Patients: A Comparative Analysis of SARS-CoV-2 Variant Waves in a Romanian Hospital Setting.

Briciu V, Leucuta D, Muntean M, Radulescu A, Cismaru C, Topan A Pathogens. 2023; 12(12).

PMID: 38133336 PMC: 10871103. DOI: 10.3390/pathogens12121453.

Incidence of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without antiviral medications: A retrospective study.

Mousavi Movahed S, Akhavizadegan H, Dolatkhani F, Akbarpour S, Nejadghaderi S, Najafi M PLoS One. 2023; 18(10):e0292746.

PMID: 37819890 PMC: 10566706. DOI: 10.1371/journal.pone.0292746.

The efficacy and safety of remdesivir alone and in combination with other drugs for the treatment of COVID-19: a systematic review and meta-analysis.

Chen C, Fang J, Chen S, Rajaofera M, Li X, Wang B BMC Infect Dis. 2023; 23(1):672.

PMID: 37814214 PMC: 10563317. DOI: 10.1186/s12879-023-08525-0.

References

DerSimonian R, Laird N . Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3):177-88. DOI: 10.1016/0197-2456(86)90046-2. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009; 6(7):e1000097. PMC: 2707599. DOI: 10.1371/journal.pmed.1000097. View

Jayk Bernal A, Gomes da Silva M, Musungaie D, Kovalchuk E, Gonzalez A, Delos Reyes V . Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2021; 386(6):509-520. PMC: 8693688. DOI: 10.1056/NEJMoa2116044. View

Khwaja A . KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012; 120(4):c179-84. DOI: 10.1159/000339789. View

Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V . Remdesivir for the treatment of COVID-19. Cochrane Database Syst Rev. 2021; 8:CD014962. PMC: 8406992. DOI: 10.1002/14651858.CD014962. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497-506. PMC: 7159299. DOI: 10.1016/S0140-6736(20)30183-5. View

Hammond J, Leister-Tebbe H, Gardner A, Abreu P, Bao W, Wisemandle W . Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. N Engl J Med. 2022; 386(15):1397-1408. PMC: 8908851. DOI: 10.1056/NEJMoa2118542. View

Candido de Almeida D, Franco M, Dos Santos D, Santos M, Maltoni I, Mascotte F . Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients. PLoS One. 2021; 16(5):e0251048. PMC: 8148326. DOI: 10.1371/journal.pone.0251048. View

10.

Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A . An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021; 27(12):1826-1837. PMC: 8149166. DOI: 10.1016/j.cmi.2021.05.020. View

11.

Hansrivijit P, Qian C, Boonpheng B, Thongprayoon C, Vallabhajosyula S, Cheungpasitporn W . Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis. J Investig Med. 2020; 68(7):1261-1270. DOI: 10.1136/jim-2020-001407. View

12.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

13.

Spinner C, Gottlieb R, Criner G, Lopez J, Cattelan A, Soriano Viladomiu A . Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11):1048-1057. PMC: 7442954. DOI: 10.1001/jama.2020.16349. View

14.

Silva N, de Sene Amancio Zara A, Figueras A, Oliveira de Melo D . Potential kidney damage associated with the use of remdesivir for COVID-19: analysis of a pharmacovigilance database. Cad Saude Publica. 2021; 37(10):e00077721. DOI: 10.1590/0102-311X00077721. View

15.

Gerard A, Laurain A, Fresse A, Parassol N, Muzzone M, Rocher F . Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database. Clin Pharmacol Ther. 2020; 109(4):1021-1024. DOI: 10.1002/cpt.2145. View

16.

Guan W, Ni Z, Hu Y, Liang W, Ou C, He J . Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020; 382(18):1708-1720. PMC: 7092819. DOI: 10.1056/NEJMoa2002032. View

17.

Kalil A, Mehta A, Patterson T, Erdmann N, Gomez C, Jain M . Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021; 9(12):1365-1376. PMC: 8523116. DOI: 10.1016/S2213-2600(21)00384-2. View

18.

Palevsky P . COVID-19 and AKI: Where Do We Stand?. J Am Soc Nephrol. 2021; 32(5):1029-1032. PMC: 8259685. DOI: 10.1681/ASN.2020121768. View

19.

Legrand M, Bell S, Forni L, Joannidis M, Koyner J, Liu K . Pathophysiology of COVID-19-associated acute kidney injury. Nat Rev Nephrol. 2021; 17(11):751-764. PMC: 8256398. DOI: 10.1038/s41581-021-00452-0. View

20.

Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y . Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395(10236):1569-1578. PMC: 7190303. DOI: 10.1016/S0140-6736(20)31022-9. View